30
Participants
Start Date
October 25, 2023
Primary Completion Date
October 31, 2029
Study Completion Date
October 31, 2029
Atezolizumab
"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
NOT_YET_RECRUITING
Belfast City Hospital, Belfast
RECRUITING
University Hospital Birmingham, Birmingham
NOT_YET_RECRUITING
Birmingham Children's Hospital, Birmingham
RECRUITING
Bristol Royal Hospital for Children, Bristol
RECRUITING
Bristol Haematology and Oncology Centre, Bristol
RECRUITING
Addenbrooke's Hospital, Cambridge
RECRUITING
Velindre Cancer Centre, Cardiff
NOT_YET_RECRUITING
Cardiff Children's Hospital, Cardiff
RECRUITING
Western General Hospital, Edinburgh
RECRUITING
The Beatson Hospital, Glasgow
RECRUITING
Royal Hospital for Children Glasgow, Glasgow
RECRUITING
Leicester Royal Infirmary, Leicester
RECRUITING
Alder Hey Hospital, Liverpool
RECRUITING
University College London Hospital, London
RECRUITING
Guy's Hospital, London
RECRUITING
Great Ormond Street Hospital, London
NOT_YET_RECRUITING
Royal Manchester Children's Hospital, Manchester
RECRUITING
The Christie Hospital, Manchester
RECRUITING
Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
RECRUITING
Great North Children's Hospital, Newcastle
RECRUITING
Freeman Hospital, Newcastle
RECRUITING
Churchill Hospital, Oxford
RECRUITING
John Radcliffe Hospital, Oxford
RECRUITING
Weston Park Hospital, Sheffield
RECRUITING
Sheffield's Children's Hospital, Sheffield
RECRUITING
Southampton General Hospital, Southampton
RECRUITING
The Royal Marsden Hospital, Sutton
Lead Sponsor
University of Manchester
OTHER
University of Birmingham
OTHER
Royal Marsden NHS Foundation Trust
OTHER
Hoffmann-La Roche
INDUSTRY
Cancer Research UK
OTHER